BRIEF-Shanghai Henlius Biotech Announces Key Findings Of Independent Investigation

Reuters2023-12-20

Dec 20 (Reuters) - Shanghai Henlius Biotech Inc

:

* KEY FINDINGS OF INDEPENDENT INVESTIGATION AND INTERNAL CONTROL REVIEW

* INDEPENDENT INVESTIGATION FOUND PART OF CO'S IPO PROCEEDS WERE RAISED THROUGH AMTD GLOBAL MARKETS LIMITED

* CFO AT TIME SIGNED MANAGEMENT AGREEMENT ON BEHALF OF CO ON 25 SEPTEMBER 2019, AS FOUND BY INDEPENDENT INVESTIGATION

* CO PURCHASED PROMISSORY NOTES ISSUED BY THREE PRIVATE ENTITIES WITH TOTAL PRINCIPAL AMOUNT OF US$86.4 MILLION

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment